| Name | Number of Reports | Reference(s) | Data Source | |
|---|---|---|---|---|
| 1 | Imatinib Mesylate | FAERS: 5 | US FAERS | |
| 2 | rofecoxib | FAERS: 3 | US FAERS | |
| 3 | tofacitinib | FAERS: 3 Canada Vigilance: 1 | Canada Vigilance US FAERS | |
| 4 | Celecoxib | FAERS: 1 | US FAERS | |
| 5 | Fluoxetine | FAERS: 1 | US FAERS | |
| 6 | Ondansetron | FAERS: 1 | US FAERS | |
| 7 | Paroxetine | FAERS: 1 | US FAERS | |
| 8 | Tacrolimus | FAERS: 1 | US FAERS | |
| 9 | apremilast | FAERS: 1 | US FAERS | |
| 10 | Clobazam | OFFSIDES | ||
| 11 | Ethosuximide | OFFSIDES | ||
| 12 | Ezetimibe | OFFSIDES | ||
| 13 | Lamotrigine | OFFSIDES | ||
| 14 | Nebivolol | OFFSIDES | ||
| 15 | Octreotide | OFFSIDES | ||
| 16 | Paroxetine | Canada Vigilance: 1 | Canada Vigilance | |
| 17 | Vigabatrin | OFFSIDES | ||
| 18 | tetrazepam | OFFSIDES |
Page last updated at 2020-05-25 10:01:57 (Asia/Shanghai) | You are visitor No. 120240
Copyright © 2019-2020 Laboratory of Molecular Modeling and Design, Shanghai Key Laboratory of New Drug Design, School of Pharmacy, East China University of Science and Technology. All rights reserved.